内部人交易雷达

美国 · SEC Form 4 · 快照日期： 2026-10-19 · 构建时间： 2026-10-19 · English

← 美国市场 · 覆盖记录

美国 · SEC FORM 4

Rallybio Corp

RLYB · Nasdaq · CIK 0001739410 · Healthcare · Biotechnology

内部人信号

53.3 / 100

1 位买方 · 14 条买入交易行 · $4.2M 买入总额

为什么有这个信号？

买方广度较低
买入规模较强
角色中等
近期性较低
确信度较强
评分构成

每条进度条表示其对当前分数的贡献；权重和公式保持不变。

Cluster+7.0 / 35
买入规模+21.6 / 25
角色+14.0 / 20
近期性+0.8 / 10
确信度+10.0 / 10

哪些因素限制了当前分数？

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ 角色得分低 · 买入者中职位最高的是：TenPercentOwner（CEO、董事长和持股 10% 以上的股东得分最低）
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。

买方广度与集中度

合资格买方1
买入集中度100%最大买方： ADAR1 Capital Management, LLC; Schneeberger Daniel · $4.2M
聚集买入 · 15天1 insider峰值活动： 2026-05-04–2026-05-19

Roles in the peak window: TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

内部人活动时间轴

申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。

AprMayJunJulAugSepOct
ADAR1 Capital Management, LLC; Schneeberger DanielTenPercentOwner
●●●●●●●●
Lieber Jonathan IChief Financial Officer
○○
Liu HuiDirector
○
Chung WendyDirector
○
Boudreau Helen MDirector
○
Uden StephenChief Executive Officer
○
● 买入▼ 卖出○ 其他

Showing the six most active owners; 1 additional owner(s) remain in Form 4 申报证据.

信号历史

53.3 / 100

最新留档分数

→ +0.0 pts相对上一个留档快照
  1. 53.4
  2. 53.4
  3. 53.3
  4. 53.3
  5. 53.3

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

近期 Form 4 活动

14买入
1卖出
11其他 Form 4 交易行
12SEC 申报 · 365天
买入14 qualifying P line(s) · 180 days
卖出0 sale line(s) · 仅供背景
其他10 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

市场背景

市场背景补充近期价格表现与风险信息，不影响内部人信号。

价格表现

1M
+1.6%
3M
+7.1%
6M
+101.7%
12M
+269.4%

波动率与流动性

波动率
97.4%
Beta
—
平均每日成交额
USD 329,378

估值

市值
USD 90.4M
P/E
—

基本面

利润率
—
ROE
-15.5%
细分行业
Biotechnology

市场数据

价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-07-30 · Status: PASS

空头余额

空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。

空头股数
49,245
上期报告
55,556
日均成交量
10,095
回补天数
4.9

FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。

历史股票买入

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting owner类型证券股数平均价格估算金额来源
2026-05-19ADAR1 Capital Management, LLC; Schneeberger Daniel买入 (P)Common Stock10,200USD 13.98USD 142,560SEC 申报 ↗
2026-05-18ADAR1 Capital Management, LLC; Schneeberger Daniel买入 (P)Common Stock6,009USD 13.98USD 84,006SEC 申报 ↗
2026-05-15ADAR1 Capital Management, LLC; Schneeberger Daniel买入 (P)Common Stock300USD 13.90USD 4,170SEC 申报 ↗
2026-05-13ADAR1 Capital Management, LLC; Schneeberger Daniel买入 (P)Common Stock79,259USD 13.99USD 1,108,810SEC 申报 ↗
2026-05-12ADAR1 Capital Management, LLC; Schneeberger Daniel买入 (P)Common Stock800USD 13.83USD 11,064SEC 申报 ↗
2026-05-11ADAR1 Capital Management, LLC; Schneeberger Daniel买入 (P)Common Stock50,000USD 14.00USD 700,000SEC 申报 ↗
2026-05-05ADAR1 Capital Management, LLC; Schneeberger Daniel买入 (P)Common Stock35,101USD 14.00USD 491,414SEC 申报 ↗
2026-05-04ADAR1 Capital Management, LLC; Schneeberger Daniel买入 (P)Common Stock120,804USD 13.97USD 1,687,359SEC 申报 ↗
2023-03-14Lieber Jonathan I买入 (P)Common Stock5,000USD 5.21USD 26,050SEC 申报 ↗
2022-03-21Fryer Jeffrey M买入 (P)Common Stock3,000USD 8.04USD 24,120SEC 申报 ↗
2022-01-19Fryer Jeffrey M买入 (P)Common Stock1,400USD 8.70USD 12,180SEC 申报 ↗
2022-01-13Uden Stephen买入 (P)Common Stock5,000USD 9.15USD 45,752SEC 申报 ↗
2022-01-12Uden Stephen买入 (P)Common Stock5,000USD 10.55USD 52,750SEC 申报 ↗
2022-01-11MACKAY MARTIN买入 (P)Common Stock4,496USD 10.65USD 47,882SEC 申报 ↗
2022-01-10MACKAY MARTIN买入 (P)Common Stock5,504USD 10.10USD 55,590SEC 申报 ↗

Form 4 申报证据

26 transaction lines in the latest 365-day window; 69 in local history.

日期申报人类型证券股数平均价格估算金额来源
2026-10-12Hopfner Robert Lorne期权行权／转换 (M)Common Stock14,820USD 7.41USD 109,875SEC 申报 ↗
2026-10-09Lieber Jonathan I期权行权／转换 (M)Common Stock3,910USD 6.08USD 23,773SEC 申报 ↗
2026-10-06Uden Stephen期权行权／转换 (M)Common Stock22,456USD 6.08USD 136,532SEC 申报 ↗
展开近期 Form 4 证据 (17 grouped rows)
日期申报人类型证券股数平均价格估算金额来源
2026-10-12Hopfner Robert Lorne期权行权／转换 (M)Common Stock14,820USD 7.41USD 109,875SEC 申报 ↗
2026-10-09Lieber Jonathan I期权行权／转换 (M)Common Stock3,910USD 6.08USD 23,773SEC 申报 ↗
2026-10-06Uden Stephen期权行权／转换 (M)Common Stock22,456USD 6.08USD 136,532SEC 申报 ↗
2026-09-29Lieber Jonathan I期权行权／转换 (M)Common Stock5,000USD 6.08USD 30,400SEC 申报 ↗
2026-09-24Liu Hui期权行权／转换 (M)Common Stock12,044USD 6.06USD 72,941SEC 申报 ↗
2026-09-16Chung Wendy期权行权／转换 (M)Common Stock3,562USD 2.38USD 8,478SEC 申报 ↗
2026-07-06Boudreau Helen M期权行权／转换 (M)Common Stock3,562USD 2.38USD 8,478SEC 申报 ↗
2026-05-19ADAR1 Capital Management, LLC; Schneeberger Daniel买入 (P)Common Stock10,200USD 13.98USD 142,560SEC 申报 ↗
2026-05-18ADAR1 Capital Management, LLC; Schneeberger Daniel买入 (P)Common Stock6,009USD 13.98USD 84,006SEC 申报 ↗
2026-05-15ADAR1 Capital Management, LLC; Schneeberger Daniel买入 (P)Common Stock300USD 13.90USD 4,170SEC 申报 ↗
2026-05-13ADAR1 Capital Management, LLC; Schneeberger Daniel买入 (P)Common Stock79,259USD 13.99USD 1,108,810SEC 申报 ↗
2026-05-12ADAR1 Capital Management, LLC; Schneeberger Daniel买入 (P)Common Stock800USD 13.83USD 11,064SEC 申报 ↗
2026-05-11ADAR1 Capital Management, LLC; Schneeberger Daniel买入 (P)Common Stock50,000USD 14.00USD 700,000SEC 申报 ↗
2026-05-05ADAR1 Capital Management, LLC; Schneeberger Daniel买入 (P)Common Stock35,101USD 14.00USD 491,414SEC 申报 ↗
2026-05-04ADAR1 Capital Management, LLC; Schneeberger Daniel买入 (P)Common Stock120,804USD 13.97USD 1,687,359SEC 申报 ↗
2026-02-23Lieber Jonathan I卖出 (S)Common Stock789USD 5.06USD 3,992SEC 申报 ↗
2026-02-18Lieber Jonathan I奖励／授予 (A)Common Stock2,500USD 0.00USD 0SEC 申报 ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

快照与身份

快照日期2026-10-19
排名版本US-v1.2
数据质量PASS ELIGIBLE · —
股票代码RLYB
CIK0001739410
行业Healthcare
细分行业Biotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
交易所Nasdaq

数据覆盖

本地 Form 4 历史69 transaction lines from 2021-07-28 to 2026-10-12
30 P purchase lines · 15 S sale lines · 24 other lines
SEC 公司申报打开 SEC 申报 ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.